ADMA Biologics

ADMA · NASDAQ

$11.23+$0.16 (+1.45%)TodayMarket closed · Oct 20, 7:38 PM ET

Prev close $11.07

ADMA analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $17.34 (+54.4% upside)

Low: $12.12
Now: $11.23
High: $22.05

Upgrades and downgrades

The latest rating actions, newest first

ADMA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Mizuho	Jul 15, 2026	Maintains	Outperform	$20.00 → $17.00	56%
Canaccord Genuity	May 7, 2026	Maintains	Buy	$21.00 → $18.00	57%
Mizuho	May 7, 2026	Maintains	Outperform	$24.00 → $20.00	56%
Canaccord Genuity	Apr 21, 2026	Initiates	Buy	$21.00	57%
Mizuho	Apr 13, 2026	Maintains	Outperform	$30.00 → $24.00	56%
Cantor Fitzgerald	Mar 26, 2026	Downgrade	Overweight → Neutral	—	41%

The case for and against

Updated May 1, 2025

Bull case

ADMA Biologics has demonstrated substantial top and bottom-line outperformance, leading to a notable increase in revenue guidance, projecting $415 million for FY 2024 and $465 million for FY 2025, substantially above prior estimates. Furthermore, the company's net income expectations have also been revised upwards, with projections indicating FY 2024 net income exceeding $120 million and FY 2025 net income reaching over $165 million. With adjusted EBITDA expected to surpass $160 million in FY 2024 and $215 million in FY 2025, this solid financial performance highlights ADMA's robust growth potential and enhanced manufacturing capabilities.

Bear case

ADMA Biologics faces significant risks that contribute to a negative outlook, primarily due to challenges in securing adequate plasma supply and establishing the market presence of its products, ASCENIV and BIVIGAM, which have seen slower-than-expected uptake. Competitive pressures from larger companies in the IVIG space pose additional threats to ADMA's sales potential, while the complex manufacturing process for IVIG products carries inherent risks, including potential FDA scrutiny due to operational issues. Lastly, the reliance on third-party services for crucial manufacturing processes heightens the likelihood of product delays and adds further uncertainty to the company’s financial stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.